论文部分内容阅读
目的观察健脾化瘀方联合肝动脉化疗栓塞术(TACE)治疗肝癌的临床疗效。方法将204例肝癌患者随机分为试验组和对照组各102例。试验组给予健脾化瘀方联合TACE治疗,对照组仅给予TACE治疗。分别于治疗前后检测2组患者血清血管内皮生长因子(VEGF)水平,观察2组患者治疗效果、不良反应发生情况及预后。结果试验组患者治疗后近期有效率为91.18%显著高于对照组的74.51%,不良反应发生率显著低于对照组,治疗后复发率低于对照组,半年存活率高于对照组,中位生存期亦显著高于对照组,差异均有统计学意义(P<0.05)。结论健脾化瘀方联合TACE治疗肝癌具有良好的疗效和预后结局,并可有效降低患者血清VEGF水平,且VEGF水平与疗效和预后结局呈负相关。
Objective To observe the clinical efficacy of Jianpi Huayu decoction combined with transcatheter arterial chemoembolization (TACE) in the treatment of liver cancer. Methods Totally 204 patients with liver cancer were randomly divided into experimental group and control group with 102 cases each. The experimental group was given Jianpi Huayu decoction combined with TACE treatment, while the control group only given TACE treatment. The levels of serum vascular endothelial growth factor (VEGF) in two groups were detected before and after treatment. The therapeutic effect, the incidence of adverse reactions and the prognosis of the two groups were observed. Results The effective rate of the trial group was 91.18%, which was significantly higher than that of the control group (74.51%). The incidence of adverse reactions was significantly lower in the trial group than in the control group. The recurrence rate after treatment was lower than that in the control group, and the half-year survival rate was higher than that in the control group Survival was also significantly higher than the control group, the difference was statistically significant (P <0.05). Conclusion Jianpi Huayu Recipe combined with TACE has a good curative effect and prognosis for hepatocellular carcinoma, and can effectively reduce the serum level of VEGF. The level of VEGF is negatively correlated with curative effect and prognosis.